The highest-tier scientific papers are indeed Lancet and Nature, which are extremely difficult to publish in.
The paper highlights that cells (lympahtic endothelial cells) express a receptor (VEGFR3) on their surface during abnormal development (ie. during abnormal proliferation, as in cancer). The role of midkine (neurite growth-promoting factor 2), a protein expressed during this abnormal development, is also highlighted in the biology of these cells.
These results highlight the role of midkine in cancer cell development, Cellmid's therapeutic target. However, the basic premise of the paper is that VEGFR3 is a good early screening tool for abnormal formation of lymphatic vessels and tissue. The market may not have responded because the paper highlights a screening tool for early cancer detection, instead of treating midkine as a therapeutic target per se.
As @mightypirate (25282695) mentioned in another Cellmid thread, these results are indirectly good, in a space with lots of scientific papers being published and lots of money being thrown around.
Add to My Watchlist
What is My Watchlist?
